Systematic (IUPAC) name | |
---|---|
5-ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole | |
Clinical data | |
Pregnancy cat. | ? |
Legal status | ℞ Prescription only |
Routes | Oral |
Identifiers | |
CAS number | 173352-39-1 |
ATC code | None |
PubChem | CID 9862937 |
ChemSpider | 8038633 |
UNII | HDO6HX6NZU |
Chemical data | |
Formula | C15H21N3O2S |
Mol. mass | 307.410 g/mol |
SMILES | eMolecules & PubChem |
|
|
(verify) |
(what is this?)
Afobazole is an anxiolytic drug launched in Russia in the early 2000s. It produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions, making it more selective in action than many currently used drugs for this application. Its mechanism of action remains poorly defined however, with GABAergic, NGF and BDNF release promoting, MT1 receptor antagonism, MT3 receptor antagonism, and sigma agonism all thought to have some involvement.[1][2][3][4][5] Clinical trials have shown afobazole to be well tolerated and reasonably effective for the treatment of anxiety, although it has yet to be introduced into widespread clinical use outside of Russia.[6]
|
|